|
|||||
|
|
Patient‐reported outcomes from EMILIA,a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer |
|
| Authors: | Manfred Welslau MD Veronique Diéras MD Joo‐Hyuk Sohn MD Sara A Hurvitz MD Deepa Lalla PharmD PhD Liang Fang PhD Betsy Althaus PharmD BCOP Ellie Guardino MD PhD David Miles MD |
| Institution: | 1. Medical Office Hematology, Aschaffenburg, Germany;2. Institut Curie, Paris, France;3. Yonsei University College of Medicine, Seoul, South Korea;4. UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology, Los Angeles, California;5. Genentech, Inc., South San Francisco, California;6. Mount Vernon Cancer Centre, Northwood, United Kingdom |
| Abstract: | |
| Keywords: | ado‐trastuzumab emtansine T‐DM1 HER2‐positive quality of life breast cancer antibody– drug conjugate |